5,414 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Andrew Hill Investment Advisors Inc.

Key Points

• Andrew Hill Investment Advisors Inc. has acquired 5,414 shares of Thermo Fisher Scientific Inc. for approximately $2,196,000, making it the firm's 24th largest holding.
• Thermo Fisher announced a quarterly dividend of $0.43 per share, set to be paid on October 15, 2023, which equates to a 0.4% dividend yield.
• The company's latest quarterly earnings report revealed an EPS of $5.36, exceeding analysts' estimates, with anticipated FY 2025 guidance set between 22.220-22.840 EPS.

Andrew Hill Investment Advisors Inc. acquired a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 5,414 shares of the medical research company's stock, valued at approximately $2,196,000. Thermo Fisher Scientific makes up approximately 1.8% of Andrew Hill Investment Advisors Inc.'s holdings, making the stock its 24th largest position.

Several other hedge funds have also recently modified their holdings of the business. Bernard Wealth Management Corp. acquired a new stake in Thermo Fisher Scientific during the fourth quarter valued at $25,000. CBIZ Investment Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares in the last quarter. Ameriflex Group Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at about $30,000. Anderson Financial Strategies LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $30,000. Finally, Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific in the first quarter worth approximately $31,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Trading Down 0.2%

NYSE TMO traded down $1.08 during trading hours on Friday, reaching $480.02. The company's stock had a trading volume of 4,241,401 shares, compared to its average volume of 1,433,914. The stock has a market cap of $181.26 billion, a P/E ratio of 27.76, a P/E/G ratio of 2.56 and a beta of 0.75. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $623.77. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a fifty day simple moving average of $472.01 and a 200-day simple moving average of $449.50.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. During the same period in the previous year, the business posted $5.37 EPS. The firm's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Analyst Ratings Changes

Several analysts have weighed in on TMO shares. Royal Bank Of Canada set a $561.00 price objective on Thermo Fisher Scientific and gave the stock an "outperform" rating in a report on Tuesday, September 2nd. Evercore ISI reduced their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. HSBC restated a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Finally, Raymond James Financial reissued an "outperform" rating and set a $535.00 price objective (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.